Fibromuscular dysplasia secondary prevention

Revision as of 13:07, 25 April 2018 by Anmol Pitliya (talk | contribs)
Jump to navigation Jump to search

Fibromuscular dysplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fibromuscular dysplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiorgram

X-ray

CT

MRI

Arteriography

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Management Guidelines

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ASA/ACCF/AHA Guideline Recommendations

Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries

Case Studies

Case #1

Fibromuscular dysplasia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fibromuscular dysplasia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fibromuscular dysplasia secondary prevention

CDC on Fibromuscular dysplasia secondary prevention

Fibromuscular dysplasia secondary prevention in the news

Blogs on Fibromuscular dysplasia secondary prevention

Directions to Hospitals Treating Fibromuscular dysplasia

Risk calculators and risk factors for Fibromuscular dysplasia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

  • There are no established measures for the secondary prevention of [disease name].

OR

  • Effective measures for the secondary prevention of [disease name] include:
    • [Strategy 1]
    • [Strategy 2]
    • [Strategy 3]

References

Template:WH Template:WS